Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Aileens Pharma S R L has 1 pending office action in Biotechnology & Pharmaceuticals. This action is assigned to 1 distinct examiner and 1 distinct art unit. The current prosecution is concentrated in a single technical area with one point of contact. This suggests a streamlined approach where the company is currently focused on a specific technical advancement rather than a broad array of filings.
MOREAU, NASHARA LOUISE is the busiest examiner, handling the 1 pending office action. With only 1 distinct examiner and 1 distinct art unit, the prosecution strategy is streamlined. This allows for a focused interaction with the USPTO to resolve the single outstanding matter. This centralized examination structure allows for a more predictable interaction with the patent office, as there are no competing examiner styles or differing art unit standards to navigate for the current pending matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOREAU, NASHARA LOUISE | 1 | 80.0% | -100.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18563001 | BACTERIAL CELL WALL BOUND TO A MUCOPOLYSACCHARIDE, USES THEREOF AND PROCESS FOR ITS PRODUCTION | MOREAU, NASHARA LOUISE | 8d overdue |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18563001 | BACTERIAL CELL WALL BOUND TO A MUCOPOLYSACCHARIDE, USES THEREOF AND PROCESS FOR ITS PRODUCTION | MOREAU, NASHARA LOUISE | 1655 | §101§103§112 | Final Rejection | 8d overdue | Pending | Nov 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial